StudyFinder



Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

4 Study Matches

A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Pallidotomy for the Treatment of Advanced, Idiopathic Parkinson's Disease With Medication-refractory Moderate to Severe Motor Complications

This registry is a prospective, multicenter, international, single arm, observational post-approval registry with follow-up at 3, 6, and 12 months, and annually for 5 years. The proposed registry will enroll 60 subjects and will be conducted at approximately 10 centers worldwide.

Call 214-648-5005
studyfinder@utsouthwestern.edu, Charlton.Starcke@UTSouthwestern.edu

Bhavya Shah
ALL
30 Years to 99 Years old
This study is NOT accepting healthy volunteers
NCT05539196
STU-2022-1006
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Men and women, age 30 years and older. * Subject undergoing a planned an Exablate procedure for their Parkinson's Disease with Motor Complications per local institution standard of care. * Subject is willing to cooperate with the Registry requirements including compliance with the regimen and completion of all Registry visits. * Subject has signed and received a copy of the approved informed consent form.
Exclusion Criteria:
* Subject does not agree to participate or is unlikely to participate for the entirety of the Registry.
DEVICE: Exablate Pallidotomy, Unilateral
Movement Disorders, Neurology, Parkinsons Disease
UT Southwestern
I'm interested
Share via email
See this study on ClinicalTrials.gov

Motor Network Physiology

The brain networks controlling movement are complex, involving multiple areas of the brain. Some neurological disorders, like Parkinson's disease (PD) and essential tremor (ET), cause abnormalities in these brain networks. Deep brain stimulation is a treatment that is used to treat these types of neurological diseases and is thought to help patients by modulating brain networks responsible for movement. Levodopa medication is also used to modulate this brain networks in patients with PD. The overall objective is to develop a unified theory of basal ganglia thalamocortical (BGTC) circuit dynamics that accounts for disease symptomatology, movement, and their inter-relationship. The underlying hypothesis, is that the rigidity and bradykinesia of PD are fundamentally related to excessive functional coupling across nodes in the BGTC motor circuit impeding effective information flow. In this research, the investigator will take advantage of the unique opportunity provided by awake deep brain stimulation surgery to learn more about how the brain functions in a diseased state and how deep brain stimulation changes these networks to make movement more normal. The investigator will simultaneously assess cortical and subcortical electrophysiology in relation to clinical symptoms and behavioral measures and in response to deep brain stimulation, cortical stimulation, and pharmacologic therapy in patients undergoing Deep Brain Stimulation (DBS) implantation surgery.

Call 214-648-5005
studyfinder@utsouthwestern.edu, Sahil.Chilukuri@UTSouthwestern.edu

Nader Pouratian
ALL
18 Years to 89 Years old
NA
This study is NOT accepting healthy volunteers
NCT04957095
STU-2021-0376
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
* Diagnosis of Parkinson's disease who have been recommended to undergo deep brain stimulation for management of their movement disorder * Preoperative MRI without evidence of cortical or subdural adhesions or vascular abnormalities * Willingness and ability to cooperate during conscious operative procedure for up to 40 minutes
Exclusion Criteria:
* Patients with recent use (within one week) of anticoagulant or antiplatelet agents * Neurocognitive testing indicating amnestic cognitive deficits
DRUG: Apomorphine Injectable Solution, OTHER: Subcortical Stimulation
Parkinson Disease, Essential Tremor, Brain and Nervous System
deep brain stimulation, levodopa medication, motor cortex, basal ganglia, thalamus
UT Southwestern
I'm interested
Share via email
See this study on ClinicalTrials.gov

Facilitating Diagnostics and Prognostics of Parkinsonian Syndromes Using Neuroimaging

The goals of this study are: 1) to identify biomarkers using neuroimaging that are associated with progression rate using statistical methods, and 2) to identify biomarkers that are associated with the differential diagnosis of Parkinson's disease and atypical parkinsonism.

Padraig E O'Suilleabhain, MD padraig.osuilleabhain@utsouthwestern.edu

ALL
Not specified
This study is also accepting healthy volunteers
NCT03872102
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
For Aim 1: * Diagnosis of Parkinson disease * Existence of sufficient clinical data from previous UTS Southwestern longitudinal study to determine progression rate (categorized as fast or slow) * Availability of suitable matched participant in the alternate progression group (fast or slow) * Willingness to participate in the imaging studies required for this study and to provide written informed consent For Aim 2: PD subjects will be recruited in accordance with the MDS Clinical Diagnostic Criteria for PD. * Duration of PD (since diagnosis) is \< 5 years * Willing to participate in imaging and clinical scoring visits, and provide written informed consent * Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move) MSA subjects will be recruited in accordance with the Second Consensus Statement on Diagnosis of Multiple System Atrophy. * Duration of MSA (since diagnosis) is \< 5 years * Willing to participate in imaging and clinical scoring visits, and provide written informed consent * Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study) PSP subjects will be recruited in accordance with the MDS Criteria for Diagnosis of Progressive Supranuclear Palsy and must meet the designation of "probable PSP" for inclusion. * Willing to participate in imaging and clinical scoring visits, and provide written informed consent * Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study) Control subjects will be recruited who meet the following criteria: * Roughly age and sex matched with the subjects in the PD cohort * No history or examination findings suggestive of any neurodegenerative disease * Normal gait, balance, and eye movements for age * No clinical evidence for symptomatic orthostatic hypotension * Willing to participate in imaging and clinical scoring visits, and provide written informed consent * Subject and investigator agree that it is highly likely subject will be able to participate throughout the 2-year study period (no plans to move away during the study)
Exclusion Criteria:
For Aims 1 and 2: * Any contraindications to undergoing the multimodal imaging program * All females of child-bearing potential, between the ages of 18-55, will be excluded from the study, unless they are confirmed to be not pregnant with a pregnancy test prior to scanning * This study will require constant clear communication throughout the duration of the study; therefore, non-English speakers will be excluded * Right-handed finger amputees * Cast on right hand or fingers at the time of enrollment * Has clinically significant liver, kidney, lung, metabolic or hormone disturbances which pose safety risk * Has a current clinically significant heart disease that poses a safety risk * Has a current clinically significant infectious disease or a medical comorbidity which poses a safety risk * Has a history of relevant severe drug allergy or hypersensitivity * Have a history of drug, alcohol, or substance dependence or abuse within the last year, or prior prolonged history of dependence or abuse * Currently undergoing chemotherapy or radiation for cancer * Recreational drug use in past six months * Central nervous systems disease or brain injury that would preclude participation in this study * Psychiatric or neurological disorder that would preclude participation in this study * Inability to keep or maintain research appointments For Aim 1: * Severe disease progression such that participation in the imaging tests would be impossible or difficult * Non-availability of a suitable matched participant in the alternate progression group (fast or slow) For Aim 2: PD subjects
• Unequivocal cerebellar abnormalities
• Downward vertical gaze limitation or slowing of downward saccades
• Diagnosis of behavioral variant frontotemporal dementia or primary progressive aphasia
• Parkinsonian features restricted to the lower limbs for \> 3 years
• Treatment with dopamine blockers or depleters in a time course consistent with drug induced parkinsonism
• Absence of an observable response to high dose levodopa despite moderate disease severity
• Expert considers a diagnosis of alternative syndrome more likely than PD
• Rapid progression of gait impairment requiring wheelchair within 5 years of onset
• Complete absence of progression of motor symptoms over 5 years unless due to treatment
• Early bulbar dysfunction within the first 5 years since diagnosis
• Inspiratory respiratory dysfunction (stridor or frequent sighs)
• Severe autonomic failure in the first 5 years
• Recurrent falls (\>1 per year) because of impaired balance in the first 3 years
• Disproportionate dystonic anterocollis or hand contractures of hands or feet within 10 years
• Absence of any of the common non-motor features of PD despite 5 years of disease
• Otherwise unexplained pyramidal tract signs (weakness, hyperreflexia, or extensor toe signs)
• Bilateral symmetric parkinsonism MSA subjects
• Clinically significant neuropathy
• Hallucinations not induced by drugs
• Onset after age 75 years
• Family history of ataxia or parkinsonism
• White matter lesions suggesting multiple sclerosis PSP subjects
• Predominant, otherwise unexplained impairment of episodic memory, suggestive of AD (Alzheimer's disease)
• Predominant, otherwise unexplained autonomic failure, e.g., orthostatic hypotension (orthostatic reduction in blood pressure after 3 minutes standing \> 30 mm Hg systolic or \> 15 mm Hg diastolic), suggestive of multiple system atrophy or Lewy body disease
• Predominant, otherwise unexplained visual hallucinations or fluctuations in alertness, suggestive of dementia with Lewy bodies
• Predominant, otherwise unexplained multisegmental upper and lower motor neuron signs, suggestive of motor neuron disease (pure upper motor neuron signs are not an exclusion criterion)
• Sudden onset or step-wise or rapid progression of symptoms, in conjunction with corresponding imaging or laboratory findings, suggestive of vascular etiology, autoimmune encephalitis, metabolic encephalopathies, or prion disease
• History of encephalitis
• Prominent appendicular ataxia
• Identifiable cause of postural instability, e.g., primary sensory deficit, vestibular dysfunction, severe spasticity, or lower motor neuron syndrome Control subjects a. In the investigator's opinion, an unsuitable candidate to serve as a control
Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
I'm interested
Share via email
See this study on ClinicalTrials.gov

Brain Networks and Consciousness

General anesthesia (GA) is a medically induced state of unresponsiveness and unconsciousness, which millions of people experience every year. Despite its ubiquity, a clear and consistent picture of the brain circuits mediating consciousness and responsiveness has not emerged. Studies to date are limited by lack of direct recordings in human brain during medically induced anesthesia. Our overall hypothesis is that the current model of consciousness, originally proposed to model disorders and recovery of consciousness after brain injury, can be generalized to understand mechanisms of consciousness more broadly. This will be studied through three specific aims. The first is to evaluate the difference in anesthesia sensitivity in patients with and without underlying basal ganglia pathology. Second is to correlate changes in brain circuitry with induction and emergence from anesthesia. The third aim is to evaluate the effects of targeted deep brain stimulation on anesthesia induced loss and recovery of consciousness. This study focuses on experimentally studying these related brain circuits by taking advantage of pathological differences in movement disorder patient populations undergoing deep brain stimulation (DBS) surgery. DBS is a neurosurgical procedure that is used as treatment for movement disorders, such as Parkinson's disease and essential tremor, and provides a mechanism to acquire brain activity recordings in subcortical structures. This study will provide important insight by using human data to shed light on the generalizability of the current model of consciousness. The subject's surgery for DBS will be prolonged by up to 40 minutes in order to record the participant's brain activity and their responses to verbal and auditory stimuli.

Call 214-648-5005
studyfinder@utsouthwestern.edu, Sahil.Chilukuri@UTSouthwestern.edu

Nader Pouratian
All
18 Years and over
This study is NOT accepting healthy volunteers
NCT04502550
STU-2021-0396
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Willingness and ability to cooperate during conscious operative procedure for up to 40 minutes
• Clinical diagnosis of Parkinson's disease or essential tremor
• Preoperative MRI without evidence of cortical or subdural adhesions or vascular abnormalities
Exclusion Criteria:

• Patients with recent use (within one week) of anticoagulant or antiplatelet agent use
• Neurocognitive testing indicating amnestic cognitive deficits
• History of intolerance of propofol or medical indications to use an anesthetic other than propofol
Drug: Propofol
Loss of Consciousness, Parkinson Disease, Essential Tremor, Anesthesia, Brain and Nervous System
general anesthesia, deep brain stimulation, basal ganglia, thalamus, sensorimotor cortex
UT Southwestern
I'm interested
Share via email
See this study on ClinicalTrials.gov